The analysis showed that the median survival time was 15.7 months for chemotherapy alone and 20.8 months for chemotherapy with immune cell therapy, with an increase in life expectancy of approximately 5 months. A correlation between gender and cancer tissue type and the prognosis of immune cell therapy was also confirmed, especially for female lung adenocarcinoma patients who showed good results with the combination of immune cell therapy and chemotherapy. According to Japanese media reports, Medinet, a Japanese company dedicated to cutting-edge medical technology innovation, announced on March 23 that its partner, Seta Clinic Group, has summarized the research results related to the combination of immune cell therapy and chemotherapy for non-small cell lung cancer. The research results show that the combination of immune cell therapy and chemotherapy has a significant prognostic advantage for non-small cell lung cancer compared to the use of anti-cancer drugs alone. It is known that non-small cell lung cancer accounts for 80% of lung cancers in Japan and is known to have a poor prognosis. In this study, a research group led by Dr. Kazuro Iwai of Seta Clinic Group, together with seven major hospitals in Tokyo, including University Hospital, analyzed the efficacy of immunotherapy and chemotherapy on non-small cell lung cancer using a large number of cases. Among the cases analyzed were 540 patients who were treated between November 2001 and December 2006. The analysis showed that the median survival time was 15.7 months for chemotherapy alone and 20.8 months for chemotherapy with immune cell therapy, an increase of about 5 months. The association between gender and cancer tissue type and the prognosis of immune cell therapy was also confirmed, especially in women with lung adenocarcinoma who showed good results with the combination of immune cell therapy and chemotherapy.